Full-Time

Vice President

Drug Discovery Immuno-Oncology

Confirmed live in the last 24 hours

Vir Biotechnology

Vir Biotechnology

501-1,000 employees

Develops monoclonal antibodies for infectious diseases

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$290k - $340kAnnually

Expert

No H1B Sponsorship

San Francisco, CA, USA

Expectation of 4 days per week in office.

Category
Public Health
Biology Lab & Research
Biology & Biotech

You match the following Vir Biotechnology's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Ph.D. or equivalent advanced degree in a relevant scientific discipline (immunology and immuno-oncology background strongly preferred)
  • 15+ years of experience in the pharmaceutical/biotechnology industry, with a focus on immune-therapies for oncology
  • Subject matter expert in cancer immunology with a significant publication record in the field
  • Thorough knowledge and expertise in preclinical drug discovery of large molecules and understanding of the oncology landscape
  • History of building relationships and promoting engagement across all partners, including senior management, scientific and clinical advisory boards, academic and biopharma partners, and CROs
  • Sound business acumen with a pragmatic, results-oriented leadership style
  • Prior experience leading large teams and management skills to inspire and develop individuals
  • Strong communication and presentation skills with the ability to generate scientific reports and presentations
  • Demonstrated ability to work in a fast-paced, dynamic environment
Responsibilities
  • Lead a group of scientists focused on immuno-oncology, offering strategic direction and mentorship
  • Oversee the oncology drug discovery pipeline, from early-stage research through preclinical development
  • Utilize extensive experience and expertise in immunology to create overarching strategies for cancer immunotherapies
  • Oversee and manage teams who partner with external collaborations to discover targets and molecules for advancement
  • Provide updates to senior leadership on status of program activities/strategies, identify potential risks and challenges, and develop mitigation strategies
  • Stay abreast of the latest developments in immune-oncology and drug development, incorporating relevant insights into program strategies
  • Ensure financial resources are effectively allocated and managed to support achievement of the priority objectives for translational biology group

Vir Biotechnology develops treatments for infectious diseases by harnessing the immune system, using a proprietary platform for monoclonal antibodies (mAbs) combined with machine learning and artificial intelligence. Their pipeline includes clinical candidates for hepatitis B, hepatitis delta, and HIV, as well as monoclonal antibodies targeting influenza, COVID-19, and human papillomavirus. What distinguishes Vir from competitors is its collaboration with industry leaders and organizations to expedite scientific advancements. The company's goal is to transform lives by addressing unmet medical needs.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$640.6M

Headquarters

San Francisco, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in AI-driven drug discovery benefits Vir's AI capabilities.
  • The rise of personalized medicine aligns with Vir's monoclonal antibody focus.
  • Global pandemic preparedness funding supports Vir's broad-spectrum antiviral therapies.

What critics are saying

  • Leadership instability due to key executive resignations may disrupt operations.
  • Job cuts and facility closures indicate potential financial strain.
  • Struggles to diversify beyond COVID-19 antibody success may impact revenue growth.

What makes Vir Biotechnology unique

  • Vir Biotechnology uses AI-enhanced capabilities for monoclonal antibody development.
  • The company focuses on immune system manipulation for targeted therapies.
  • Vir's pipeline includes a potential functional cure for chronic hepatitis B.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive healthcare coverage

Employer matched 401(k)

Employee stock purchase plan

Childcare assistance

Tuition reimbursement

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

2%

2 year growth

4%
U.S. Securities and Exchange Commission
Dec 5th, 2024
vir-10q_20200331.htm

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Investing.com
Aug 1st, 2024
Vir Biotechnology inks major deal with Sanofi unit

Moreover, Vir Biotechnology has entered into a significant licensing agreement with Amunix Pharmaceuticals, Inc., a Sanofi company.

MarketScreener
Aug 1st, 2024
Vir Biotechnology to Cut 140 Jobs in Restructuring to Focus on Hepatitis Drug Development

Vir Biotechnology to cut 140 jobs in restructuring to focus on hepatitis drug development.

Simply Wall St
May 5th, 2024
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

Vir Biotechnology, Inc. (NASDAQ:VIR) just released its quarterly report and things are looking bullish.

Investing.com
Apr 18th, 2024
Vir Biotechnology CFO Sung Lee to step down in May

Vir Biotechnology Inc. (NASDAQ:VIR) announced Monday that Executive Vice President and Chief Financial Officer Sung Lee will resign from his position effective May 3, 2024.